The company set out to develop a new "five-year strategy"
Release time:
2020-08-14
Company started to formulate a new "five-year strategy"
Three-year business plan for each enterprise
News from our newspaper 2018 is the last year of the implementation of the Group Company's "2014-2018 Development Strategy" and each enterprise's "2016-2018 Business Plan". Recently, the company has begun to prepare a new "2019-2023 Development Strategy", and the three-year business plan of each professional company and directly affiliated enterprise will also be prepared simultaneously.
Group Company's "2014 - 2018 Development Strategy" was compiled and completed in the first half of 2014 , further defining the development concept of "strengthening the main business through cooperation and innovation, standardizing science and seeking development", and proposing the role of cement as a base maker and a cost leader in the regional market. Medicine is led by scientific and technological innovation, do the business philosophy of the market leader in the field of segmentation, and on this basis, formulate specific strategic objectives and development direction. In order to further implement this strategic plan, in 2015 , the group company required each industrial sector to prepare its own three-year business plan, which is not only the refinement and extension of the group company's development strategy, but also the work guide of each professional company and directly affiliated enterprise.
Since the implementation of the "Five-Year Strategy" and "Three-Year Plan", the company's various businesses have developed by leaps and bounds, and its operating efficiency has also been greatly improved. The company's total assets, net assets, and profitability of its main business have all improved to a certain extent. However, compared with the expected goals in the "Five-Year Strategy", there are obvious gaps in many projects such as business development and growth rate. Therefore, before the preparation of the new "five-year strategy", the company requires the investment department to conduct full research and demonstration, carefully analyze the internal and external environment, and make scientific and forward-looking predictions for the future development of various industries, so as to formulate a more realistic development plan.
At the same time, in order to clarify the short-and medium-term business development goals of each subordinate enterprise and cooperate with the new "five-year strategy", the company has recently requested each subordinate enterprise to carry out the three-year business planning of 2019 - 2021 . It is required to carefully analyze the gains and losses in the implementation of the previous "three-year plan" and have a definite target, it must have a certain depth and consider the feasibility of achieving it; the content must include but not limited to: the industry situation, market trends, major competitors, the current situation of the company, and the advantages, disadvantages, opportunities, and threats faced by the company. In-depth analysis, annual business planning objectives, implementation plans, safeguard measures, capital planning, etc. Among them, the business planning objectives should be refined into sub-objectives such as cost control, revenue and profit, economic and technical indicators, energy and resource consumption, safety and environmental protection control, and management improvement. The setting of various technical and economic indicators should be based on advanced enterprises in the industry and improved year by year. (this newspaper reporter)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page